CoChat

Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes

Pirro, Valentina, Roth, Kenneth D, Lin, Yanzhu, Willency, Jill A, Milligan, Paul L, Wilson, Jonathan M, Ruotolo, Giacomo, Haupt, Axel, Newgard, Christopher B, Duffin, Kevin L · 2022 · The Journal of Clinical Endocrinology & Metabolism
Cited by 113

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

Context: Tirzepatide substantially reduced hemoglobin A1c (HbA1c) and body weight in subjects with type 2 diabetes (T2D) compared with the glucagon-like peptide 1 receptor agonist dulaglutide. Improved glycemic control was associated with lower circulating triglycerides and lipoprotein markers and improved markers of beta-cell function and insulin resistance (IR), effects only partially attributable to weight loss. Objective: Assess plasma metabolome changes mediated by tirzepatide. Design: Phase 2b trial participants were randomly assigned to receive weekly subcutaneous tirzepatide, dulaglutide, or placebo for 26 weeks. Post hoc exploratory metabolomics and lipidomics analyses were performed. Setting: Post hoc analysis. Participants: 259 subjects with T2D. Intervention(s): Tirzepatide (1, 5, 10, 15 mg), dulaglutide (1.5 mg), or placebo. Main Outcome Measure(s): Changes in metabolite levels in response to tirzepatide were assessed against baseline levels, dulaglutide, and placebo using multiplicity correction. Results: At 26 weeks, a higher dose tirzepatide modulated a cluster of metabolites and lipids associated with IR, obesity, and future T2D risk. Branched-chain amino acids, direct catabolic products glutamate, 3-hydroxyisobutyrate, branched-chain ketoacids, and indirect byproducts such as 2-hydroxybutyrate decreased compared to baseline and placebo. Changes were significantly larger with tirzepatide compared with dulaglutide and directly proportional to reductions of HbA1c, homeostatic model assessment 2-IR indices, and proinsulin levels. Proportional to metabolite changes, triglycerides and diglycerides were lowered significantly compared to baseline, dulaglutide, and placebo, with a bias toward shorter and highly saturated species. Conclusions: Tirzepatide reduces body weight and improves glycemic control and uniquely modulates metabolites associated with T2D risk and metabolic dysregulation in a direction consistent with improved metabolic health.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/clinem/dgab722

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Research works printed but not linked: 20

  1. Tschöp, 2016, Unimolecular polypharmacy for treatment of diabetes and obesity, Cell Metab., 24, 51, 10.1016/j.cmet.2016.06.021 · DOI · Paper page
  2. Asmar, 2016, Insulin plays a permissive role for the vasoactive effect of GIP regulating adipose tissue metabolism in humans, J Clin Endocrinol Metab., 101, 3155, 10.1210/jc.2016-1933 · DOI · Paper page
  3. Wilson, 2020, The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes, Diabetes Obes Metab., 22, 2451, 10.1111/dom.14174 · DOI · Paper page
  4. Newgard, 2017, Metabolomics and metabolic diseases: where do we stand?, Cell Metab., 25, 43, 10.1016/j.cmet.2016.09.018 · DOI · Paper page
  5. White, 2019, Branched-chain amino acids in disease, Science., 363, 582, 10.1126/science.aav0558 · DOI · Paper page
  6. Gall, 2010, alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population, PLoS One., 5, e10883, 10.1371/journal.pone.0010883 · DOI · Paper page
  7. Cobb, 2016, α-hydroxybutyric acid is a selective metabolite biomarker of impaired glucose tolerance, Diabetes Care., 39, 988, 10.2337/dc15-2752 · DOI · Paper page
  8. White, 2016, Branched-chain amino acid restriction in Zucker-fatty rats improves muscle insulin sensitivity by enhancing efficiency of fatty acid oxidation and acyl-glycine export, Mol Metab., 5, 538, 10.1016/j.molmet.2016.04.006 · DOI · Paper page
  9. Tulipani, 2016, Metabolomics-guided insights on bariatric surgery versus behavioral interventions for weight loss, Obesity (Silver Spring)., 24, 2451, 10.1002/oby.21686 · DOI
  10. Gu, 2020, Distinctive metabolomics patterns associated with insulin resistance and type 2 diabetes mellitus, Front Mol Biosci., 7, 609806, 10.3389/fmolb.2020.609806 · DOI
  11. White, 2020, Muscle-liver trafficking of BCAA-derived nitrogen underlies obesity-related glycine depletion, Cell Rep., 33, 108375, 10.1016/j.celrep.2020.108375 · DOI
  12. Flores-Guerrero, 2018, Plasma branched-chain amino acids and risk of incident type 2 diabetes: results from the PREVEND prospective cohort study, J Clin Med., 7, 10.3390/jcm7120513 · DOI
  13. Glynn, 2015, Impact of combined resistance and aerobic exercise training on branched-chain amino acid turnover, glycine metabolism and insulin sensitivity in overweight humans, Diabetologia., 58, 2324, 10.1007/s00125-015-3705-6 · DOI · Paper page
  14. McGarrah, 2020, Dietary branched-chain amino acid restriction alters fuel selection and reduces triglyceride stores in hearts of Zucker fatty rats, Am J Physiol Endocrinol Metab., 318, E216, 10.1152/ajpendo.00334.2019 · DOI
  15. Walejko, 2021, Branched-chain α-ketoacids are preferentially reaminated and activate protein synthesis in the heart, Nat Commun., 12, 1680, 10.1038/s41467-021-21962-2 · DOI
  16. Yoneshiro, 2019, BCAA catabolism in brown fat controls energy homeostasis through SLC25A44, Nature., 572, 614, 10.1038/s41586-019-1503-x · DOI · Paper page
  17. Wittemans, 2019, Assessing the causal association of glycine with risk of cardio-metabolic diseases, Nat Commun., 10, 1060, 10.1038/s41467-019-08936-1 · DOI
  18. Fonseca, 2019, Reductions in insulin resistance are mediated primarily via weight loss in subjects with type 2 diabetes on semaglutide, J Clin Endocrinol Metab., 10.1210/jc.2018-02685 · DOI · Paper page
  19. Samms, 2019, 1009-P: the dual GIP and GLP-1 receptor agonist tirzepatide regulates lipid and carbohydrate metabolism through GIPR in adipose tissue, 10.2337/db19-1009-P · DOI
  20. Frias, 2019, Efficacy and safety of an expanded dulaglutide dose range: a phase 2, placebo-controlled trial in patients with type 2 diabetes using metformin, Diabetes Obes Metab., 21, 2048, 10.1111/dom.13764 · DOI · Paper page

Cited by

See all 113

Metadata

Authors
Pirro, V., Roth, K. D., Lin, Y., Willency, J. A., Milligan, P. L., Wilson, J. M., Ruotolo, G., Haupt, A., Newgard, C. B., & Duffin, K. L.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2021-10-05
Volume
107
Issue
2
Pages
363-378
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W3203975425
Cited by
113
References
21
FWCI
12.31
Type
journal article
Language
en
Open access
closed
Funders
Eli Lilly and Company

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes. https://app.cochat.ai/papers/10.1210/clinem/dgab722
The paper
Pirro, V., Roth, K. D., Lin, Y., Willency, J. A., Milligan, P. L., Wilson, J. M., Ruotolo, G., Haupt, A., Newgard, C. B., & Duffin, K. L. (2022). Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgab722

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.